November 7, 2012

Skystar's primary veterinary facility resumes production, distribution in Huxian, China

Skystar Bio-Pharmaceutical Company announced on Monday (Nov 5) that its primary production facility for veterinary medicines in Huxian, China has resumed production and distribution in October 2012.

Production was allowed to resume at the 45,000 square foot veterinary medicine facility following Good Manufacturing Process "GMP" recertification by the Ministry of Agriculture and physical receipt of a GMP certificate. The veterinary medication line contributes significant annual revenue, accounting for roughly two-thirds of Skystar's fiscal 2011 sales.

Skystar's two veterinary medicine facilities in Jingzhou and Huxian province have now resumed production and possess GMP certificates valid for five years.

Lu, Chairman and CEO, commented, "We are pleased to resume production of the Company's veterinary medication lines at both our Huxian and Jingzhou plant which was recently GMP recertified. As a leading provider of veterinary medicines in China, the Company looks forward to resuming support and providing products for the animal husbandry needs of its customer base. China's market for veterinary medicines continues to grow as the industry moves towards national production standards for livestock, poultry and aquaculture. In line with this trend, the Company's production facilities will be core to its mission of expanding the Company's footprint distribution, customer base and sales of its products. We look forward to providing an operational update and outlook to shareholders for all of our production lines when the Company reports its full fiscal year."

Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 284 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China.